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Results of heparin-bonded ePTFE-covered stents
for chronic occlusive superficial femoral artery
disease
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Suzanne Holewijn, PhD,a,e Clark J. Zeebregts, MD, PhD,d and Michel M. P. J. Reijnen, MD, PhD,a
Arnhem, Zwolle, Groningen, and Nijmegen, The Netherlands
Objective: The purpose of this study was to assess the 1-year patency rates of heparin-bonded covered stents in the
treatment of chronic occlusive disease of the superficial femoral artery (SFA).
Methods: All patients treated with a heparin-bonded endograft between April 2009 and October 2010 for chronic
occlusive disease of the SFA were prospectively gathered in a database and retrospectively analyzed. Primary, primary-
assisted, and secondary patency rates, assessed by ultrasound scanning, were analyzed at 1-year, as were the complication
rates and mortality.
Results: A total of 56 limbs were treated with a heparin-bonded covered stent in 53 patients for chronic ischemia
Rutherford category 3 (n  36), 4 (n  5), 5 (n  11), and 6 (n  1). Lesions were classified as TransAtlantic
Inter-Society Consensus (TASC)-2-B (n 9), C (n 14), and D (n 33), and the mean treated lesion length was 18.5
7.7 cm. Postoperative complications occurred in 7.5%, including hematoma (n 1), edema (n 1), pneumonia (n 1),
and urinary retention (n 1), and the 30-day mortality rate was 0%. The mean follow-up was 413 208 days. At 1 year,
the primary patency was 76%, the primary-assisted patency 82%, and the secondary patency 89%. The limb salvage rate was
100%.
Conclusions: Heparin-bonded covered stents seem to provide a valid alternative to surgical treatment of long occlusive
lesions in the SFA. Randomized trials and long-term data are required before considering the technique as a new standard
of care. ( J Vasc Surg 2012;56:118-25.)
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uPeripheral arterial disease (PAD) is a widespread prob-
lem with a prevalence of 3% to 10%, increasing to 15% to
20% over the age of 70 years.1-3 The prevalence of inter-
mittent claudication is estimated at 3% in patients aged 40
and 6% in patients aged 60.4,5 One percent of patients with
PADwill eventually develop critical limb ischemia annually.
The TransAtlantic Inter-Society Consensus (TASC) has
given recommendations for treatment strategies based on
morphologic stratification of the lesions.5 Surgery is con-
sidered the gold standard for lesions with a length of 15
cm. Endovascular alternatives and results, however, are
evolving continuously.
The introduction of nitinol stents has improved results
of endovascular treatment of chronic occlusive lesions of
the superficial femoral artery (SFA). One-year primary pa-
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118ency rates have been reported between 63% and 80% in
esions with a length of 5 cm to 11 cm.6-8 The major
imitation of endovascular treatment is the occurrence of
in-stent) re-stenosis due to intimal neo-hyperplasia. To
educe the incidence of in-stent re-stenosis, covered stents
ave been introduced. We have recently shown that these
ay reduce re-stenosis to edge stenosis only.9 Case series
ave shown 1-year primary patency rates between 44% and
3% for lesions from 8 cm up to 26 cm.10-12 McQuade et
l13 have recently published the 4-year results of a random-
zed trial comparing an above-knee prosthetic femoropop-
iteal bypass with covered stents. There were no differences
n primary or secondary patency rates between both treat-
ent modalities, and limb salvage rates were also compara-
le, indicating that covered stents may be a viable alterna-
ive for bypass surgery. The venous femoropopliteal bypass,
owever, is associated with higher patency rates when
ompared to prosthetic bypasses.14
The introduction of the heparin-bonded technology
as significantly improved patency rates of peripheral sur-
ical bypasses.15,16 Because endograft failure is often due
o acute thrombosis rather than in-stent re-stenosis, the
eparin-bonding technology has also been integrated with
ndografts. It is believed that the irreversible bonded
eparin-molecules in the inner surface of the graft may
revent thrombosis, thus further increasing their perfor-
ance. To date, no clinical studies have been published
sing heparin-bonded endografts. The purpose of the pres-
nt study was to assess the 1-year results of heparin-bonded
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of the SFA.
METHODS
Patients. All patients treated with a heparin-bonded
expanded polytetrafluoroethylene (ePTFE)-covered stent
between April 2009 and October 2010 in the Alysis Hos-
pital, located at Rijnstate in Arnhem and the Isala Clinics in
Zwolle, The Netherlands, were prospectively gathered in a
database. Two dedicated vascular surgeons (M.R. and
W.F.) and one interventional radiologist (J.O.) performed
all the procedures.
In all patients, secondary risk prevention was performed
according to the national guidelines and all patients with
intermittent claudication were initially treated with walking
exercise. Only those with unsuccessful exercise training
were indicated for intervention. The indication for endo-
vascular treatment was based on anatomic suitability and
the preference of both the patient and surgeon. Generally,
covered stents were used in lesions with a length of more
than 15 cm, whereas bare metal stents or plain balloon
angioplasty were used in shorter lesions. Anatomic suitabil-
ity consisted of an adequate inflow without a flow-limiting
stenosis in the aortoiliac arteries, a patent popliteal artery
above the P3 level with a luminal diameter of at least 4.2
mm, and at least one patent crural vessel.
Demographics, clinical status, and medical history were
noted and retrospectively reviewed. Procedural aspects and
follow-up data were retrieved. Lesions were reviewed and
scored according to the TASC-2 criteria.5 Additionally, the
lesion length, luminal vessel diameters, and the number of
patent run-off vessels were scored.
Patients with a lesion length of 5 cm were excluded
from the analysis as were patients who had undergone a
previous stent placement in the ipsilateral SFA or femoro-
popliteal bypass surgery.
Follow-up consisted of clinical assessment, including
physical examination, ankle-brachial index (ABI) measure-
ments, and duplex ultrasound scans at 1, 3, 6, and 12
months. The ABI was measured in a supine position using
a Nicolet VasoGuard (CareFusion Corporation, San Di-
ego, Calif) or a Basic 3 (Atys Medical, Soucieu en Jarrest,
France). Complications and additional treatments were
registered in the hospital files.
Definitions. Risk factors were scored according to the
Society for Vascular Surgery medical comorbidity grading
system. Re-stenosis was defined as a peak systolic velocity
(PSV) ratio2.5, as measured on ultrasound scanning. An
occlusion was defined as absence of flow in the treated
segment of the superficial femoral artery. Primary patency
was defined as the absence of re-stenosis or occlusion in the
target vessel. Primary-assisted patency was defined as pa-
tency achieved by secondary endovascular interventions to
treat re-stenosis of the target vessel. Secondary patency was
defined as patency achieved by all procedures aimed at
recanalizing an occluded endograft, thereby preserving the
endograft. Limb salvage was defined as the absence of an
above-ankle amputation. pTreatment protocol. Procedures were performed us-
ng antibiotic prophylaxis. The common femoral artery was
pproached either percutaneously or surgically, as preferred
y the treating surgeon. When there was a concomitant
esion in the common or profunda femoral artery, an end-
rterectomy was performed. Heparin (5000 IU) was ad-
inistered. The diseased segment of the SFA was passed
sing a Terumo wire (Terumo Medical Corporation, Elk-
on, Md) and a catheter, either endoluminal or subintimal,
nd a re-entry was created distally. The segment was pre-
ilated with a regular angioplasty balloon and the en-
ografts were positioned from distal to proximal with min-
mal oversizing. The entire diseased segment was covered
ith endografts and endografts were postdilated with an
ngioplasty balloon with the same size as the endograft.
ontrol angiography of the bypass and outflow vessels was
erformed routinely. In case of a percutaneous approach,
he access was closed using a closure device (Angio-Seal; St.
ude Medical, St. Paul, Minn, or Proglide; Abbott Vascu-
ar, Bruxelles, Belgium) or by manual compression.
The used endograft was the heparin-bonded Viabahn
ndoprosthesis (W. L. Gore, Flagstaff, Ariz), which is a
elf-expanding helical nitinol stent covered with a heparin-
onded thin ePTFE tube.
Postprocedural patients received statin treatment and
ual antiplatelet inhibitors, unless oral anticoagulation was
ndicated for other reasons.
Statistical analysis. Patient characteristics and charac-
eristics of the treated lesions are presented asmean and SD,
nless otherwise stated. Patency rates were determined
sing the Kaplan-Meier life-table method using PASW
tatistics software, version 18.0 (SPSS, Chicago, Ill). Log-
ank testing was used to determine possible differences in
atency rates between different subgroups (ie, different
ASC-2 lesions, level of distal anastomosis, lesion length,
iabetes mellitus, smoking, stent diameter, and number of
atent outflow vessels). A P value  .05 was considered
tatistically significant. Data are presented as mean and SD,
nless otherwise stated.
ESULTS
Patient population. During the study period a total
f 59 SFAs in 56 patients were scheduled for endovascular
reatment, of which 56 SFAs were successfully treated
95%). In the remaining three patients, the procedure was
onverted to an open femoropopliteal bypass because of the
nability to recanalize the diseased segment. The mean age
as 69.6  9.4 years and the male:female ratio was 40:13.
wenty-one patients (37.5%) were treated in the Isala
linics in Zwolle and the remaining 35 patients (62.5%) in
he Rijnstate Hospital, Arnhem.
Patient characteristics and risk factors are shown in
able I. Four patients (7.1%) had previously undergone an
ngioplasty of the SFA without stent placement, and three
thers (5.4%) had undergone an angioplasty with (n  2)
r without (n  1) stent placement of the iliac artery. One
atient already had a patent aortoiliac bypass, and another
atient had previously undergone an endarterectomy of the
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July 2012120 Lensvelt et alipsilateral common femoral artery. Two patients (3.6%) had
already undergone a minor amputation of the ipsilateral
limb.
The mean preprocedural ABI was 0.49  0.1 with a
range of 0.19 to 0.74. Nine lesions (16.1%) were classified
as TASC-2-B lesions, 14 (25%) as TASC-2-C lesions, and
the remaining 33 (58.9%) were TASC-2-D lesions. The
mean length of the lesions was 18.5  7.7 cm. Other
anatomic lesion characteristics are shown in Table II.
Procedure. Four patients were treated using local an-
esthesia only (7.5%), 26 patients were treated using spinal
anesthetics (49.1%), and the remaining 23 patients had
general anesthetics (43.4%). The use of spinal or general
anesthetics enabled a conversion to a hybrid approach or a
surgical bypass in case of a technical failure within the same
session. A percutaneous approach was used in 34 proce-
dures (60.7%). In most of these cases, access was acquired
Table I. Patient characteristics and risk factors
Risk factor No. of patients (%)
Diabetes mellitus
Yes 22 (41.6)
No 31 (58.4)
Smoking
Never 16 (30.2)
Former 10 (18.9)
Current 27 (50.9)
Hypertension
Yes 43 (81.1)
No 10 (18.9)
Hyperlipidemia
Yes 41 (77.3)
No 12 (22.7)
History of cardiac disease
No 33 (62.3)
10 years ago 8 (15.1)
Stable AP, recent MI 9 (16.9)
Non-stable AP 3 (5.7)
Neurological status
Asymptomatic 48 (90.6)
Asymptomatic CVA/TIA 4 (7.5)
Symptomatic CVA 1 (1.9)
Renal disease
No disease 42 (79.2)
Renal disease 8 (15.1)
Dialysis dependent 3 (5.7)
Pulmonary disease
Yes 13 (24.5)
No 40 (75.5)
ASA classification
I 1 (1.9)
II 22 (41.5)
III 28 (52.8)
IV 2 (3.8)
Rutherford classification
3 36 (67.9)
4 5 (9.4)
5 11 (20.8)
6 1 (1.9)
AP, Angina pectoris; ASA, American Society of Anesthesiologists; CVA,
cerebrovascular accident;MI,myocardial infarction; TIA, transient ischemic
attack.using ultrasound scan guidance. Endografts were inserted rith an exposed common femoral artery, as preferred by
ne of the surgeons, using a longitudinal incision in 11
atients (19.6%) and a concomitant endarterectomy of the
ommunal femoral artery was performed in 11 other pa-
ients (19.6%). An additional angioplasty of the iliac arter-
es, with bare metal stent placement in two of them, was
erformed in five patients in order to improve inflow, and
ngioplasty of the popliteal artery was performed in two
atients to improve outflow. Three patients underwent a
ecrotectomy and a planned minor amputation was per-
ormed in two patients. In one patient, a bilateral procedure
as combined with the treatment of an abdominal aortic
neurysm using endovascular aneurysm repair (EVAR).
ostoperatively, one patient was treated with continuous
hrombolytic therapy, because of thrombosis of the crural
rteries that already existed before the intervention. This
as also the only patient who stayed in the medium-care
nit during the 2 days of receiving thrombolytic therapy.
In 16 cases (28.6%), one endograft was used, in 18
rocedures (32.1%) two endografts were used, and in the
emaining 22 cases (39.3%) three endografts were used. In
hree cases (5.4%), the used diameter of the endograft was
mm, in 45 patients (80.4%) it was 6 mm, in seven patients
12.5%) it was 7 mm, and in one patient (1.7%) it was 8
m.
One procedure was complicated by a dissection of the
opliteal artery that was treated in the same session with an
dditional endograft. Postoperative complications oc-
urred in four of 53 patients (7.5%). One patient had a
ematoma at the puncture site that was treated conserva-
ively. One patient sustained urine retention that was con-
ervatively treated with a urinary catheter for 24 hours. One
atient developed pneumonia and was treated with antibi-
tics. One patient had an edema, without signs of deep
enous thrombosis on duplex ultrasound scan. The swell-
ng and redness, probably due to reperfusion, disappeared
uring the first postoperative month. The 30-day mortality
able II. Characteristics of the treated lesions
natomic character
No. of
patients (%)
evel of distal end of endograft
P1 36 (64.3)
P2 17 (30.3)
P3 3 (5.4)
umber of patent outflow vessels
0 1 (1.8)
1 5 (8.9)
2 11 (19.6)
3 39 (69.7)
esion length (mm) 185  77
uminal diameter superficial femoral artery (mm) 5.4  1.1
uminal diameter popliteal artery (mm) 4.6  0.75
ata are presented as mean and SD.
1, Popliteal artery cranial of the upper border of the patella; P2, popliteal
rtery between the tibia plateau and upper border of the patella; P3, popliteal
rtery below the tibia plateau.ate was 0%.
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Volume 56, Number 1 Lensvelt et al 121Patients were admitted to the hospital for a mean of
3.0 2.6 days. Most patients were admitted the day before
the intervention. Patients who underwent a percutaneous
procedure had a mean length of stay of 2.4 1.2 days, and
patients with an open approach were admitted for 3.6 
2.5 days. The mean postoperative ABI was 1.00, with a
range of 0.74 to 1.17.
Postoperatively, 37 patients (69.8%) were treated with
the combination of acetylsalicylic acid 80 mg and clopid-
ogrel 75 mg, eight patients (15.1%) received acetylsalicylic
acid 80 mg with dipyridamol 400 mg, and four patients
(7.5%) were treated by acetylsalicylic acid 80 mg only. Four
patients (7.5%) were treated by Coumadin derivates because
of other indications. All patients were treated with statins.
Clinical outcome. All but one patient were clinically
improved after placement of the endograft(s) (Fig 1). The
Preprocedural Rutherford category
   3
n=38
  4
n=5
  5
n=12
  6
n=1
1
3
4
1
29
1
2
1
1
1
7
3
1
1
Fig 1. Individual changes in the Rutherfmedian Rutherford category improved from category 3 arange, 3-6) preoperatively to category 0 (range, 0-4) post-
peratively (P  .001). There was one patient that did not
mprove clinically having an early endograft failure and she
as treated with a surgical femoropopliteal bypass. The
ubset of patients that were treated for critical limb ischemia
n  18) had all improved. Sixteen patients (88.9%) im-
roved from critical ischemia to claudication (Rutherford
ategory 1-3) and the others were asymptomatic. At 1-year
ollow-up, the freedom from target lesion revascularization
as 92.6%.
Patency. The mean follow-up was 413  208 days.
he 1-year primary patency was 76.2%, the 1-year primary-
ssisted patency was 81.7%, and the secondary patency rate
as 89.0% (Fig 2). During follow-up, no major amputa-
ions were performed.
A univariate analysis of risk factors, commonly associ-
Postprocedural Rutherford category
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The number of endografts used seemed to have an effect on
the patency rate, although not statistically significant (P 
.097). The use of three endografts decreased the primary
patency rate by 28% and 24%, respectively, when compared
with the use of one and two endografts (Fig 3). Moreover,
patients with a single vessel run-off (n  5) tended to have
a lower, but not statistically significant, patency rate com-
pared with patients with two or three vessel run-offs.
Outcome of failures. During follow-up, the en-
dograft failed in six patients (10.1%). In all but 1 patient,
the Rutherford category at time of failure was similar or
lower when compared to the preoperative Rutherford cat-
egory. The other patient went from Rutherford category 3
to category 4.
In two patients with a preprocedural Rutherford classi-
fication of 3 and 4, respectively, the occlusion was found
during routine duplex scan surveillance without having
clinical symptoms. The other four patients returned with
symptoms and were all initially treated by chemical throm-
bolysis. In one patient, the endograft then remained patent
for another 9 months before it finally failed. This patient
was treated with a below-knee ePTFE bypass due to the
absence of usable vein conduit. In the other three patients,
thrombolysis failed and they were treated with a venous
Fig 2. Kaplan-Meier survival curve showing primary pa
heparin-bonded endografts.above-knee femoropopliteal bypass. The distal runoff did oot change after failure of the endograft, when compared
o the preoperative state.
ISCUSSION
The present study shows the results of the first prospec-
ive cohort of patients treated in our centers with a heparin-
onded covered stent for chronic occlusive disease of the
FA. Based on our data, we conclude that the use of
eparin-bonded covered stents for this indication is feasi-
le, safe, and related with a good clinical outcome. This
ndicates that the use of heparin-bonded endografts might
e a valid alternative for surgery in this specific group of
atients. The technique, however, may also be considered
s an extra treatment option before even considering a
urgical reconstruction. In our series, failure of the endolu-
inal bypass did not lead to any major amputations or
orsening of the clinical status, which confirms the obser-
ation of McQuade et al13 that the use of covered stents in
FA occlusive disease is not related to an increased ampu-
ation rate due to covering collaterals in case of failure.
Femoropopliteal bypass surgery is related to morbidity,
ncluding early postoperative complications such as wound
ealing problems in 5% to 44% and edema in up to 40% to
00%.17-20 The minimally invasive character of an endovas-
ular reconstruction may well decrease morbidity in these
, primary-assisted patency, and secondary patency of thetencyften frail patients. The overall complication rate in our
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Volume 56, Number 1 Lensvelt et al 123study was only 7.5%, which then again may seem high for
an endovascular procedure, emphasizing the vulnerability
of this patient group. There were no wound healing distur-
bances and only one patient had a self-limiting postopera-
tive edema. Comparative studies with either bare metal
stents and surgical bypass, assessing both patency rates and
quality of life, such as the SUrgical versus PERcutaneous
Bypass (SUPERB) and the Viabahn vs Bare Nitinol Stent
(VIBRANT) in the treatment of long lesion (8 cm)
superficial femoral artery occlusive disease trials, are essen-
tial in defining the role of heparin-covered endografts in the
treatment algorithm of chronic occlusive SFA disease.21
In the last decade, multiple case series and few random-
ized trials have been published focusing on nonheparin-
bonded endografts for SFA occlusive disease. Treatment
strategies greatly varied, making comparisons inappropri-
ate. The previous studies showed 1-year primary patency
rate varying between 44% and 93% with large variation in
treatment length (between 7 and 26 cm).10-12 More-
over, there were large differences in the postinterven-
Table III. Primary patency rates of the heparin-bonded
endografts in relation to risk factors for failure
Risk factor
No. of
patients
Patency
(%)
P
value
TASC-2 classification .575
B 9 77.8
C 14 85.7
D 33 69.7
Level distal anastomosis .598
P1 36 72.2
P2 17 82.4
P3 3 66.7
Lesion length .790
15 cm 17 76.5
15 cm 39 74.4
Diabetes mellitus .528
Yes 24 78.1
No 32 70.8
Smoking .758
No 16 81.3
Former 13 76.9
Current 27 70.4
Endograft diameter .562
5 3 100
6 45 71.1
7 7 85.7
8 1 100
Number of used endografts
1 16 87.5 .09
2 18 83.3
3 22 59.1
Number of patent outflow vessels .513
0 1 100
1 5 40
2 11 72.7
3 39 79.5
P1, Popliteal artery cranial of the upper border of the patella; P2, popliteal
artery between the tibia plateau and upper border of the patella; P3,
popliteal artery below the tibia plateau; TASC, TransAtlantic Inter-
Society Consensus.tional antiplatelet strategy. In most series, patients were created with acetylsalicylic acid, whereas in half of them,
lopidogrel was added for 6 weeks to over 3 months. A
tudy focusing on endovascular treatment of popliteal ar-
ery aneurysms showed that the use of clopidogrel was the
nly predictor of outcome.22 In contrast to previous stud-
es, patients were consequently treated with statins in our
eries, according to current guidelines on secondary risk
revention. Statins not only lower cholesterol but may also
educe the incidence of re-stenosis by their anti-inflamma-
ory, antiproliferative, and antithrombogenic effects.23
In the study of McQuade et al,13 5 mm endografts
eemed to perform worse compared 6- and 7-mm en-
ografts at 2-year follow-up.24 In the present study, we
ould not confirm this observation using heparin-bonded
ndografts, although our 5-mm group was very small.
urther risk analysis did not reveal any significant predict-
ng factor for failure. The use of three stents was associated
ith a nonsignificant 25% decrease in 1-year patency when
ompared to the use of one or two endografts. The num-
ers, however, were low and the lack of statistical signifi-
ance may well represent a type II error. Multiple zones of
verlap may decrease flexibility of the device, thereby pos-
ibly reducing performance, and have also been associated
ith an increased incidence of stent fractures after endovas-
ular treatment of popliteal artery aneurysms.25 Fortu-
ately, with the introduction of a 25-cm endograft in 2010,
he use of more than two stents is usually no longer
ecessary. Moreover, patients with a single vessel run-off
eemed to be prone for failure in our series. However, the
ow number of patients with a single vessel run-off in this
tudy renders any conclusion unreliable.
With the introduction of the heparin-bonded technol-
gy in the endograft, the design of the stent has also been
hanged in order to reduce edge stenosis. The proximal
dge of the endograft no longer has a straight, but a
ontoured edge, that reduces infolding in case of oversiz-
ng, maintaining laminar blood flow and thus preventing
ntimal hyperplasia. The results of the present study may
herefore not be attributed to the heparin-bonding tech-
ology only.
Whether the use of covered stents for long chronic
cclusions of the SFA is cost-effective may not be con-
luded from the present data. The use of covered stents is
ikely to increase procedural costs. Additionally, endovas-
ular techniques are often related to a higher incidence of
einterventions in order to maintain patency. In our series,
nly four patients required an additional angioplasty pro-
edure to prevent failure. On the other hand, the mean
ospital stay and complication rate is usually lower due to
ts minimal invasive character. Further studies focusing on
ost-effectiveness are indicated. Prospective randomized
rials are needed to compare the current gold standards,
are metal stents, and venous bypass vs heparin-bonded
PTFE-covered stent grafts, which should also include
ost-effective analyses. Moreover, comparative studies with
he newly developed drug-eluting stents are essential before
onsidering the use of endografts as a routine treatment.
ry pat
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July 2012124 Lensvelt et alIn conclusion, the heparin-bonded endoluminal bypass
is associated with acceptable patency rates and is related to
a low morbidity and mortality rate. Furthermore, it does
not exclude the later placement of a venous bypass. Ran-
domized trials are indicated before considering the tech-
nique as a new standard of care and to elucidate the place of
the technique in the treatment algorithm of chronic SFA
occlusive disease.
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